ZTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zoetis is not a strong buy right now for a beginner long-term investor with $50,000-$100,000, and I would not chase it immediately. The stock has some long-term appeal from its animal-health franchise and hedge fund accumulation, but the recent downgrade cycle, multiple price target cuts, lawsuit overhang, and bearish moving averages outweigh the near-term setup. Since you are impatient and want a direct answer, my view is HOLD, not BUY, at this price.
ZTS is trading at 78.07, just above the pivot level of 77.831, with support at 74.026 and resistance at 81.635. Momentum is mixed: MACD histogram is positive and expanding, which is constructive, but the overall moving average structure remains bearish with SMA_200 > SMA_20 > SMA_5. RSI_6 at 29.015 suggests the stock is near oversold rather than clearly strong. The stock trend model points to modest upside potential over the next day, week, and month, but the broader trend still looks weak. Overall, the price action shows stabilization, not a confirmed uptrend.
["Hedge funds are buying, with buying amount up 228.26% over the last quarter.", "Zoetis still has a strong long-term animal-health business and premium portfolio.", "Citi recently reiterated a Buy rating and sees Solensia returning to growth in fiscal 2026.", "Price has pulled back sharply, which may create value appeal if fundamentals stabilize."]
["Multiple class-action lawsuits were announced on 2026-05-28 and 2026-05-29, creating a fresh legal overhang.", "Analyst sentiment has weakened: Argus downgraded to Hold, and several firms cut price targets materially.", "Recent commentary points to difficult Q1 results, softer macro conditions, and declining vet visit trends.", "Bearish moving-average structure confirms the stock is still in a downtrend.", "Congress trading shows 1 sale and 0 purchases in the last 90 days, signaling caution."]
Latest quarter financials were not provided in the dataset, so I cannot assess the exact quarter’s revenue or earnings figures. However, analyst commentary around the most recent quarter describes the report as difficult, with estimate cuts and concern about slower organic growth. The latest quarter season appears to be Q1 2026, and the market reaction plus multiple target reductions suggest growth trends were softer than expected.
Analyst ratings have turned more cautious recently. Argus downgraded ZTS to Hold from Buy on 2026-05-27. Citi remains Buy but lowered its target to $112 from $145. Morgan Stanley cut its target to $115 from $160 while keeping Overweight. UBS lowered targets and stayed Neutral, JPMorgan cut sharply but stayed Overweight, and Stifel remained Hold. Wall Street is split, but the direction of revisions is negative: price targets are falling and the consensus tone is more cautious than before. Pros view: high-quality animal-health franchise, premium product positioning, and long-term pet spending trends. Cons view: slowing growth, weak recent quarter, competitive concerns, and legal headline risk.
